Orchard Therapeutics plc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ORTX research report →
About the company
Orchard Therapeutics plc is a biopharmaceutical firm dedicated to developing gene-based treatments for severe and often fatal rare conditions, operating across the United Kingdom, European Union, and the United States. Their innovative gene therapy strategy involves modifying a patient's own hematopoietic stem cells, converting them into a therapeutic cellular drug that can address the illness with just one dose. The company markets Strimvelis, a gammaretroviral therapy approved for treating adenosine deaminase-severe combined immunodeficiency (ADA-SCID).
- CEO
- Hubert Baburaj Gaspar
- IPO
- 2018
- Employees
- 166
- HQ
- London, GB
Price Chart
- Market Cap
- $380.11M
- P/E
- -27.38
- P/S
- 54.41
- P/B
- 2.17
- EV/EBITDA
- -45.77
- Div Yield
- 0.00%
- Gross Margin
- 65.17%
- Op Margin
- -452.22%
- Net Margin
- -112.84%
- ROE
- -5.12%
- ROIC
- -15.86%
- Revenue
- $6.99M · 1346.38%
- Net Income
- $-7,883,000 · 78.31%
- EPS
- $-0.61 · 79.18%
- Op Income
- $-31,592,000
- FCF YoY
- 35.71%
- 52W High
- $16.72
- 52W Low
- $4.24
- 50D MA
- $16.30
- 200D MA
- $9.35
- Beta
- 0.55
- Avg Volume
- 105.22K
Get TickerSpark's AI analysis on ORTX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 24, 24 | Secor Alicia | sell | 46,000 |
| Jan 24, 24 | Secor Alicia | sell | 105,000 |
| Jan 24, 24 | GERAGHTY JAMES A | sell | 46,000 |
| Jan 24, 24 | GERAGHTY JAMES A | sell | 105,000 |
| Jan 24, 24 | GERAGHTY JAMES A | sell | 44,391 |
| Jan 24, 24 | THOMAS FRANK E | sell | 335,000 |
| Jan 24, 24 | THOMAS FRANK E | sell | 405,590 |
| Jan 24, 24 | THOMAS FRANK E | sell | 179,390 |
| Jan 24, 24 | THOMAS FRANK E | sell | 92,081 |
| Jan 24, 24 | Rowland Charles A Jr | sell | 46,000 |
Our ORTX coverage
Recent articles, reports, and earnings notes.
No research on ORTX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ORTX report →Similar companies
Peers in the same neighborhood.